Related Experiment Videos
Immunosuppressive drugs in pregnancy
F Z Ghandour1, T C Knauss, D E Hricik
1Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Advances in Renal Replacement Therapy
|February 26, 1998
Summary
Pregnancy after organ transplantation is generally successful, especially with established immunosuppressants like cyclosporine, azathioprine, and steroids. Careful management is crucial due to potential risks to mother and fetus from newer agents.
Area of Science:
- Transplantation Medicine
- Reproductive Medicine
- Pharmacology
Background:
- Successful pregnancies are increasingly common in female organ transplant recipients.
- Pregnancy in this population requires management as a high-risk condition, focusing on preventing and treating rejection episodes.
- The landscape of immunosuppressive drugs has expanded, necessitating evaluation of their safety during pregnancy.
Purpose of the Study:
- To summarize the current understanding of pregnancy outcomes in organ transplant recipients.
- To highlight the importance of managing high-risk pregnancies in this cohort.
- To discuss the safety profiles of various immunosuppressive agents during pregnancy.
Main Methods:
- Review of data from a national registry on pregnancy outcomes in organ transplant recipients.
- Analysis of pregnancy success rates in patients on specific immunosuppressive drug combinations.
- Assessment of available information on newer immunosuppressive agents in pregnancy.
Main Results:
- Pregnancy is generally successful for patients maintained on combinations of cyclosporine, azathioprine, and steroids.
- Limited data exist regarding the safety of newer immunosuppressive agents during pregnancy.
- Established immunosuppressive regimens show a favorable safety profile in this context.
Conclusions:
- Pregnancy in organ transplant recipients can be successful but requires vigilant management.
- Physicians must weigh the benefits of immunosuppression against potential risks to mother and fetus.
- Further research is needed on the safety of novel immunosuppressive drugs in pregnant transplant patients.